The FDA con­firms that Sarep­ta neme­sis Ronald Farkas has left the agency

The FDA’s Ronald Farkas was one of Sarep­ta’s tough­est crit­ics. When the biotech made a bid to win an ac­cel­er­at­ed ap­proval for their Duchenne mus­cu­lar dy­s­tro­phy drug, the MD from the di­vi­sion of neu­rol­o­gy prod­ucts shot them down at every turn, spurn­ing the biotech’s shaky case that a tiny tri­al with just 12 pa­tients had pro­vid­ed any ev­i­dence to make it wor­thy of be­com­ing the first ap­proved drug to treat the lethal, rare dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER